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Abstract
This article presents data on the current best evidence-based clinical practices and controversies surrounding
folic acid supplementation/fortification for the prevention of neural tube defects (NTDs) during early preg-
nancy. Formatted as a series of ten clinical questions, answers and extensive discussion are provided for each
point. We assess the history and evidence behind supplementation and fortification, racial/ethnic disparities
in NTDs on a global scale, and present information on risk factors for NTDs other than dietary folic acid
deficiency. Also discussed are public health challenges, including disparities in NTD rates, population-wide
monitoring of NTDs, and tracking safety data in the post-fortification era. Emerging data are also reviewed
regarding the role folic acid may play in malignant processes, cardiovascular disease, male fertility, and other
medical conditions.
 
Introduction
Neural tube defects (NTDs) are common and devastating
congenital malformations of the central nervous system.
The two most common, anencephaly (a total or partial
absence of the brain tissue, skull, and overlying skin) and
spina bifida (herniation of spinal cord, meninges, or both
through a defect in the spine), comprise >90% of cases.
Both arise from incomplete closure of the neural tube early
in gestation, often before a woman is even aware that she
might be pregnant [1]. NTDs are a worldwide problem,
with approximately 300,000 affected newborns every year
and 3,000 cases per year in the United States alone [2]. A
2005 report from the Centers for Disease Control (CDC)
estimated the United States rates for spina bifida and
anencephaly at 17.96 and 11.11 per 100,000 live births,
respectively [3].
NTDs cause substantial morbidity and mortality for new-
borns and lead to staggering financial and emotional costs.
Prenatal diagnosis is now widely available in the United
States, with second trimester maternal alpha-fetoprotein
analysis and fetal ultrasound identifying >80% of cases.
Anencephaly results in in utero death, or death within a
few days of birth. In contrast, children afflicted with spina
bifida suffer from physical disabilities including paralysis,
bowel and bladder incontinence, learning disabilities, and
excess mortality well into childhood and adult years,
despite advances in medical and surgical care [4]. The
financial cost of NTDs, principally the medical and sur-
gical care of spina bifida, is high, with estimates approx-
imating $250,000 lifetime cost per case in the United
States [2].
Although the exact etiology of these defects is not yet fully
understood, it is likely multifactorial involving a complex
interplay of genetic and environmental components. Sup-
port for the genetic component comes from the well-docu-
mented higher recurrence rate among families with a pre-
viously affected pregnancy, as well as among twins [5].
Specific polymorphisms have been identified that may
increase risk [6], but the higher risk observed in certain
ethnicities, such as the Irish [7] and Mexican Americans
[8] provides further evidence suggesting a genetic com-
ponent. In addition, siblings of affected individuals have
a 10-fold increase in having a NTD affected pregnancy
themselves. Finally, couples with a prior affected preg-
nancy have a risk of NTD in a subsequent pregnancy that
is 3- to 5-fold higher than couples with no prior history
[9]. Evidence for environmental factors comes from the
variation in risk based on socioeconomic status and neigh-
borhood conditions [10,11], seasonal variation [12], and
geography [7,13–15].
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nThe most well studied of the numerous potential environ-
mental factors contributing to NTDs is the protective
effect of folic acid delivered during the periconceptual
period. Folate is a water soluble B vitamin that acts as a
cofactor in one-carbon transfer reactions and plays a cen-
tral role in nucleic acid biosynthesis [16]. Exactly how
folic acid works to prevent NTDs is currently unclear;
many questions remain about the processes underlying
normal and abnormal neural development [17]. What is
well established, however, is that maternal folic acid
intake during the periconceptual period is effective in
reducing both recurrence and first occurrence of NTDs
[18–20].
Few opportunities are present in the public health arena
where a primary prevention such as folic acid supplemen-
tation can effectively target the catastrophic health out-
come of NTD. Unfortunately, putting prevention into
practice has been much more difficult than initially antici-
pated, and numerous controversies exist about some of the
most important folic acid related issues facing women and
public health authorities worldwide. Some of these con-
tentious issues include the optimal dose of supplemental
folic acid, the safety of folic acid, the optimal level of for-
tification (and if this is even effective), and the root causes
of NTDs in different populations. This report addresses
these issues as well as highlights areas of emerging
research.
1. What are the DRIs (Dietary Reference
Intakes) for folic acid?
The recommended daily allowance of folic acid for NTD
prevention depends on obstetrical history. For women
with a prior history of NTD affected pregnancy, a 4.0 mg
daily dose starting at least one month prior to conception
and continuing throughout the first trimester is the current
United States recommendation [21]. This dose was ini-
tially recommended in 1991 after the results of the MRC
trial were published, which showed that a 4.0 mg daily
dose was effective in preventing NTD in women with a
prior affected pregnancy [20]. For women with no prior
affected pregnancy, the CDC broadened its guidelines in
1992 to include a recommended 0.4 mg daily dose for all
women of childbearing age for primary prevention of
NTD [22]. This 0.4 mg dose was based on several case
control and cohort studies (cited as above) as well as a
1992 Hungarian RCT that used 0.8 mg daily for primary
prevention. In 1999, Berry et al provided additional evi-
dence for 0.4 mg supplementation when a study carried
out in China showed significant primary prevention of
NTDs with that dose [14,15]. Although it is possible that
a lower dose could provide similar levels of protection as
0.4 mg, a RCT assessing different doses will likely never
be done due to ethical constraints.
Despite many countries throughout the world having sim-
ilar recommendations, no international consensus has
been developed and some countries still have no formal
recommendations. For example, one study of European
folic acid policies performed in 2005 found that although
13 countries had a policy in place, some of these recom-
mendations had only been disseminated ten years after the
initial CDC recommendation. Two countries, Malta and
Finland, recommended dietary sources of folate only
(non-synthetic, dietary form), and five others had no offi-
cial recommendation [23]. Interestingly, Canada’s Moth-
erisk program based in the Hospital for Sick Children,
Ontario, recently changed its folic acid guidelines to 5mg/
d for all women. This was after a recent study determined
that 40% of Ontario women were not achieving optimally
protective levels, despite fortification and supplementa-
tion [24]. Additionally, the 2007 guidelines from the
Motherisk program and the Society of Obstetricians and
Gynecologists of Canada call for 5mg/d for women with
a variety of medical and social indications, including
minority status, epilepsy, obesity, substance abuse, poor
medication compliance, and lack of birth control [25].
These recommendations are not reflective of those that are
generally available in other jurisdictions, however.
This 5mg/d recommendation is notable because it is so far
above most other recommendations and because it well
exceeds the generally accepted tolerable upper limit
(TUL) of folic acid of 1.0 mg daily. This limit is based on
concerns of possible masking of B12 deficiency anemia
(pernicious anemia) through the use of high dose folic
acid, leading to the progression of irreversible neurologic
defects resulting from B12 deficiency. Studies performed
in the 1950s showed the level of folic acid needed to cor-
rect the B12 deficiency-related anemia was about 5.0 g per
day [26]. The Institute of Medicine then established the
TUL at a somewhat arbitrary level 5 times lower than this,
at 1 mg per day. Of note, vitamin B12 levels are now rou-
tinely and easily measured in patients with unexplained
neurological symptoms [27]. Additionally, studies per-
formed post-fortification have shown no significant
change in B12 levels after fortification [28], nor has forti-
fication increased the percentage of people with B12 defi-
ciency presenting in the absence of anemia [29].
These observations are important for two reasons. The
first is that a “safety concern” is frequently mentioned
throughout the literature as an argument against wide-
spread folic acid use [4]. Indeed, potential masking of
B12 deficiency was a key reason United Kingdom health
regulators decided against fortification there in 2002; this
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nhas likewise been a contentious issue in Australia, Swit-
zerland, and other countries that continue to debate forti-
fication [30]. Secondly, the TUL was a main factor behind
the fortification policy implemented in the United States.
The fortification level was chosen to ensure that while the
majority of people would get an extra 0.1 g/d, almost no
one would cross the 1.0 mg/d threshold [30].
2. What is the minimum effective dose for
preventing NTD?
This important question is difficult to answer and has been
the subject of much debate [31,32]. A RCT focusing on a
range of doses of folic acid with incidence of NTDs as the
primary endpoint would be unethical, yet the clinical dose-
response effect is a critical issue when implementing for-
tification policies and supplementation recommendations.
This question is also challenging given the multifactorial
etiology of NTDs. The minimum effective dose may
depend on several population-based factors, such as base-
line folate status or the particular folate pathway poly-
morphisms found in a certain racial/ethnic group, for
example. Thus, the evolving understanding of the com-
plexity of NTDs makes a universal answer to this question
elusive.
Nevertheless, some researchers have attempted to address
this question within the limits placed by ethics and the
difficulties of studying such a complex process. In one
study, Daly et al (1997) looked at the amount of daily folic
acid supplementation needed to deliver protective levels
of red blood cell (RBC) folate [31]. These were previously
determined and showed an inverse relationship between
RBC folate levels and NTD risk [33]. Women with RBC
folate levels <150mcg/L were at high risk for a NTD preg-
nancy, whereas women with levels >400 mcg/L had a 60%
reduction in risk. The study focused on women of child-
bearing years, but excluded women who were either plan-
ning or at risk of pregnancy. Administration of 100, 200,
and 400 mcg/d were associated with a 22%, 41%, and 47%
reduction in NTD risk, respectively. The authors conclu-
ded that further fortification to increase levels to 400 mcg/
d or higher would offer little further benefit [31].
These findings are in contrast to a 2001 investigation that
found a continuous inverse dose response relationship and
concluded that all women should take a 5mg supplement
daily. Wald et al reviewed 13 studies that assessed the dose
of folic acid and resulting serum concentrations, and then
used data from a previous study that correlated serum lev-
els with NTD risk [34]. Significantly, however, the 13
studies only examined doses of up to 1mg/d. The resulting
model found that risk decreases proportionally to dose,
with diminishing returns at increasingly higher levels. The
authors cite risk reductions of 18%, 35%, and 53% at 100,
200, and 400 mcg/d folic acid levels, respectively. This
model also found that the effect depended on the baseline
level of serum folic acid. For example, 0.4 mg daily could
result in a protective effect between 23–54%, with a
greater effect seen with a lower baseline. The model also
extrapolated high doses of folic acid, and found an 85%
protective effect with a 5 mg/d dose of folic acid. The
authors advocated granting immediate access to 5mg tab-
lets for all women, recommending this higher dose to all
women of childbearing potential, and increasing fortifi-
cation levels to 0.6–0.8 mg per day [32,34]. Although
these recommendations have not been widely implemen-
ted, the results have been used to advocate increased for-
tification along with 5mg/d supplements [35] and to
increase Canadian recommendations to 5mg/d through the
Motherisk program [24]. However, caution is warranted
in interpreting these data because the model cannot incor-
porate the heterogeneous nature of NTDs, nor can it assess
the clinical response to folic acid that likely varies between
populations. In addition, the CDC estimates that only 50%
of NTDs are folic acid sensitive [22], a factor that is not
addressed by the model. Additional dose-response clinical
data would be helpful, and it is unfortunate that other case
control studies performed since then [36] were limited by
low sample size. If the 5 mg/d recommendations are suc-
cessfully followed in Canada, surveillance data from that
population may eventually shed some light on the issue.
3. Why and when did the United States
government mandate fortification with folic
acid?
By the time the FDA issued its recommendation (1992)
that every woman capable of pregnancy should consume
0.4mg/d folic acid for NTD prevention, evidence support-
ing this intervention had been accumulating for years—
data mostly from observational studies and nonrandom-
ized trials. However, it was not until the publication of two
landmark randomized controlled trials that the evidence
was strong enough for the United States Preventive Health
Service (USPHS) to issue its initial recommendation [22].
The Vitamins Research Council study [20] demonstrated
recurrence protection with 4mg/d, and a Hungarian RCT
showed occurrence protection with 0.8 mg/d [18]. The
evidence was subsequently strengthened by a large study
in China, demonstrating a protective effect for first-occur-
rence NTD with 0.4mg/d of folic acid [14]. The magnitude
of the effect varied, but the figure often cited on the basis
of these trials is that 50–70% of NTDs can be prevented
with folic acid supplementation.
Unfortunately, while supplementation in theory repre-
sents a straightforward method of primary prevention, the
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npractice of actually translating these recommendations
into an effective public health outreach has not been easy.
A major public health campaign was undertaken soon
after the 1992 CDC recommendation, including educa-
tional and media efforts to raise awareness of folic acid
and increase supplement use [37]. Despite this, a Gallup
poll undertaken in 1997 showed that while 66% of women
had “heard of” folic acid, just 10% knew that it could pre-
vent birth defects, only 32% of women reported taking it
daily, and a dismal 6% knew that it needed to be taken
before pregnancy [38]. These low rates of knowledge and
supplement use, combined with the reality that approxi-
mately 50% of all pregnancies in the United States are
unplanned [39], led to a general understanding that an
emphasis on supplementation as the sole means of increas-
ing folic acid consumption was likely not going to work.
Thus, in March 1996, the FDA advised folic acid fortifi-
cation of enriched grains, such as flour, bread, farina,
cornmeal, rice, and pastas, with the requirement that all be
enriched by January 1998. Whole grain products were not
considered for fortification because they contain natural
folate. Although many organizations, including the CDC,
American Academy of Pediatrics, and March of Dimes,
lobbied for fortification of 350mg folic acid per 100gm
flour, the FDA required a much lower concentration of
140mg per 100g flour, with the understanding that this
would lead to a modest 0.1 mg increase in folic acid levels
in the average American [27].
After the United States became the first country to man-
date fortification with folic acid, similar programs were
adopted in other countries. Canada adopted a nearly iden-
tical program to that of the United States, fortifying with
150mg per 100g flour less than a year later. As of 2008,
wheat flour in 67 countries has been fortified with folic
acid, representing about 30% of the world’s wheat flour,
reaching about 27% of the world’s population [40]. Six
countries fortify both wheat and maize flour, reflecting
national dietary preferences. The levels of fortification
vary widely throughout the world. In contrast to the United
States and Canada, Chile mandated fortification with 2.2g
per 100 g flour with the expectation that this would lead
to an additional intake of 0.4mg/d [41]. After a lengthy
debate in Australia, the country started fortifying all bread
flour products in September 2009 at a level of 120 mcg
per 100g flour [42]. Despite these advances in fortifica-
tion, approximately 150 countries, including those of the
European Union, have no requirement for fortification,
mostly because of safety concerns [40].
4. How many American women of childbearing
age do not get sufficient folic acid?
Despite a dramatic increase in average serum folate con-
centrations across women of all races/ethnicities since
fortification began, most nonpregnant women in the Uni-
ted States still fall short of the 0.4mg/d recommendation
[43,44]. Additionally, disparities in folate levels seen dur-
ing the pre-fortification era among women of different
racial/ethnic groups continue port-fortification [45]. The
2003–2004 National Heath and Nutrition Examination
Survey (NHANES) data showed a doubling in serum
folate concentration pre- vs. post-fortification for the pop-
ulation as a whole [46]. Using data from the 2001–2002
NHANES, Yang et al found that approximately two-thirds
of women of childbearing age were not getting the RDA
for folic acid, a number well below the 80% goal set in the
Healthy People 2010 objectives (Objectives 16–15 and
16–16) [47]. Among women who did consume 0 .4mg/d,
most (76%) achieved this with use of a daily supplement.
When data were analyzed by racial/ethnic groups, signif-
icant disparities existed. Whereas 40.5% of non-Hispanic
white women consumed >0.4 mg/d, this was reduced to
21.0% among Hispanic women and 19.1% among non-
Hispanic black women. Another study comparing pre-
fortification (1991–1994) and post-fortification (1999–
2002) NHANES data identified a similar trend [45].
Despite all racial/ethnic groups benefiting from fortifica-
tion, low RBC folate status is more concentrated among
poor and non-Hispanic black populations [45].
The reasons behind the persistent racial and ethnic var-
iance may be complicated. First, evidence shows that
minority women are less likely to take daily supplements
than are non-Hispanic whites. For example, NHANES
data documented rates of supplement use of 43.9%,
20.8%, and 19.3%, respectively, among non-Hispanic
white, Hispanic, and non-Hispanic black women [44].
Another community-based study found that Spanish-
speaking pregnant women were much less likely to have
used a multivitamin periconceptually (3.8%) than were
their English-speaking counterparts (22.4%) [48]. Chacko
et al (2003) studied young minority women treated in
reproductive health clinics in Texas, and found that only
9% of women were taking a daily multivitamin [49]. This
is significant because only 8% of women analyzed
through NHANES reached 0.4mg/d through fortified
foods alone, making supplement use a crucial determinate
of adequate folic acid intake. Other research looking at
diet and nutrition in minority populations also found lower
intakes of fruits and vegetables in these groups, and a
growing body of literature addresses the role of neighbor-
hood resources in contributing to ongoing disparities
[50,51].
Second, data from NHANES 2003–2004 revealed a stat-
istically significant drop in folate levels in 2003–2004,
compared to 1999–2000. The reasons for this drop are
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nunknown. It has been suggested that the rise in popularity
of low-carbohydrate diets during the last decade is partly
responsible [46]. Another possibility is that serum folate
levels immediately post-fortification increased almost
twice as much as originally anticipated because of forti-
fication. Authorities initially predicted an increase of 80–
130mcg/d of folic acid from fortification, although
NHANES data shows larger increases of 219mcg/d and
190mcg/d in supplement users and nonusers, respectively.
Because manufacturers are allowed to add “reasonable
overages” of folic acid to foods to ensure that the mini-
mum required levels are present throughout the shelf life
of a product [52], foods often contained an estimated 160–
175% of the mandated amount shortly after folate fortifi-
cation was initiated, although levels are now decreasing
[53]. As of the present writing, the United States does not
maintain a monitoring system for the amount of folic acid
added to foods. Some studies show manufacturer’s food
labels to be unreliable [54,52] thus making monitoring
trends in NTD rates in response to fortification difficult.
Ultimately, however, the drop in folate levels is small
compared to the magnitude of the initial rise after fortifi-
cation was initiated and affected mostly people at the
higher end of serum folate levels [46].
5. How well has fortification worked to reduce
NTDs?
It is difficult to assess the efficacy of fortification in pre-
venting NTDs for several reasons. Problems with surveil-
lance systems, scientific uncertainty, and confounding
background trends in NTD rates unrelated to fortification
all combine to produce conflicting results. The resulting
confusion makes it difficult for countries attempting to
assess current fortification levels and for others initiating
their own programs.
One fact making it difficult to measure effectiveness of
folic acid fortification is that the proportion of NTDs that
are actually folate sensitive is unknown. Decades of
research have failed to show exactly how folic acid pre-
vents NTDs. Early investigations using case control stud-
ies found a protective effect of 50–60% with supplemen-
tation, but these studies used different methods of case
reporting and differing amounts of folate [55–57]. Addi-
tionally, this effect varied depending on the population
studied, with one study of a low prevalence population
showing no effect [58]. More rigorous evidence from the
MRC RCT showed a protective effect of 72%. Although
this trial is referenced most often for the widely quoted
figure of 70% of NTDs preventable with folic acid [20],
there are several potential problems with this figure. One
is that the MRC study’s confidence interval was wide (29–
88%). Another is that the study assessed recurrence risk
in women who already had a previous NTD pregnancy.
But because most NTDs (90%) occur in women with no
history of NTD, the level of effect shown by this study
may not necessarily be generalizable to the background
population. Other investigators have estimated the per-
centage of folate sensitive NTDs at 75% globally [40] or
50% in the United States [22]. Because the actual number
of folate sensitive defects is unknown, it is difficult to
assess if current fortification levels are adequate to give
the maximum protective benefit.
It must also be acknowledged that NTD rates both in the
United States and elsewhere began falling before the ini-
tiation of folic acid fortification [59,60]. The reasons for
this decline are unclear. In Ireland, a country with histor-
ically high rates of NTDs, prevalence has been falling for
decades and cannot be accounted for by prenatal diagnosis
and pregnancy termination because abortion is not legal
in that country [61]. England and Wales have seen NTD
rates decline by 96% since the early 1970s, with 40%
attributable to prenatal diagnosis and termination and 56%
attributable to a decline in incidence [62]. A study per-
formed in Atlanta (USA) using active case ascertainment
methods for NTD detection found that rates of NTDs
declined sharply between 1968 and 2003; it was impossi-
ble to assess the impact of fortification in the setting of
such falling rates [59].
An additional problem stems from the inherent difficulties
in using United States surveillance data to track preva-
lence changes of NTDs [63]. If data used to track NTDs
are obtained only from vital records and hospital dis-
charges, then NTDs that are diagnosed prenatally (and
terminated or spontaneously aborted before 20 weeks)
would be missed. Recently, Stoll et al reported the prenatal
diagnosis rate for anencephaly and spinal bifida was
96.4% and 68.6%, respectively, along with respective ter-
mination rates of 73.2% and 40.7% that varied among
regional and ethnic groups [64]. Vital records can have
sensitivities of 86% and 40% for anencephaly and spina
bifida, respectively [65], so accurate surveillance for
NTDs is particularly challenging. Ideally, multisource
methods of case ascertainment capable of tabulating pre-
natally diagnosed, terminated cases, cases of fetal death,
and live birth should be utilized to allow for meaningful
comparisons, but these methods do not exist everywhere
in the United States.
These surveillance issues are important because the pic-
ture of the impact of fortification on NTDs changes quite
dramatically based on the completeness of case ascertain-
ment [66]. Studies that relied mostly on vital statistics
reporting found rate reductions in the range of 19–26% in
the United States, with the greater benefit seen in studies
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nwith more complete surveillance data [67,68]. In announc-
ing the decision to fortify, the CDC had projected a 50%
reduction in incidence, so these rates were met with some
disappointment and a call for higher levels of fortification.
By way of comparison, Canada with a fortification pro-
gram nearly identical to that of United States has a more
complete method of case ascertainment. After the initia-
tion of fortification, rates there dropped much more sub-
stantially, with reductions of 32% in Quebec [69], and 47–
48% in Ontario. Again, studies with the most complete
case ascertainment also showed the greatest benefit [70,
71]. Nova Scotia, for example, which had one of the high-
est reported NTD prevalence rates in the world, had a
greater magnitude of reduction of 54%. Fortification in
Canada has essentially erased geographic differences in
NTD rates across that country [69]. This phenomenon, in
which areas with the greatest NTD incidence also show
the greatest benefit from folic acid, also has been docu-
mented elsewhere [14]. Areas with highest NTD incidence
may also have the greatest number of folate sensitive
NTDs.
It is interesting that a recent study using data from the
National Birth Defects Prevention Study showed no asso-
ciation between folic acid (from supplements) or natural
folate (from dietary sources) and NTD risk. Because this
study looked at pregnancies in the post-fortification era,
the authors hypothesized that most folate-sensitive defects
have been prevented through fortification [72]. This issue
will likely remain unresolved until there is a better under-
standing of the etiology of NTDs, the role of folic acid in
the development of NTDs, and further improvements in
birth defect surveillance systems.
6. What are the racial/ethnic differences in NTD
rates in this country?
Both before and after fortification, Hispanics had the high-
est rates of NTD affected pregnancies, non-Hispanic
blacks and Asians the lowest, and non-Hispanic whites
rates that were intermediate between the two. A 2005
study by Williams et al showed that after fortification
there was a statistically significant decline in NTDs
among non-Hispanic whites and Hispanics but not among
non-Hispanic blacks. For spina bifida, rates among His-
panics (PR: 0.64; 95% CI 0.56–0.74) declined 36% pre-
to post-fortification and 34% among non-Hispanic white
births (PR: 0.66 95% CI 0.60–0.72), but showed only bor-
derline significance among non-Hispanic blacks (PR:
0.81; 95% CI 0.67–1.00) [73]. For anencephaly, the pic-
ture was similar, with both Hispanics and non-Hispanic
whites showing a similar decrease but with no significant
decline in non-Hispanic blacks [73].
The reasons for such disparities are unclear, and the
involved factors are likely go far beyond folic acid status
in different racial/ethnic groups. Indeed, one only has to
compare rates of NTD with the NHANES data on folate
status to appreciate the degree of complexity of this issue.
NTD rates by race/ethnicity are ordered as follows: His-
panics > non-Hispanic whites > non-Hispanic blacks/
Asians, but the serum and RBC folate levels as reported
by NHANES data are different: non-Hispanic whites >
Hispanics > non-Hispanic blacks [46].
The Hispanic population long has been suspected of car-
rying a large burden of the NTD cases in the United States.
Investigators have shown risk increases of 50% to 200%
in Hispanics compared to non-Hispanic whites and blacks
[6,74]. In particular, women living on the Texas-Mexico
border are at very high risk, and NTDs are endemic to this
region. In 1991, Cameron County along the border in
Texas experienced an outbreak of cases of anencephaly.
The cause of this cluster remains unknown, although envi-
ronmental exposure to a mycotoxin, fumonisin, which
infected corn flour, is suspected [75]. In an attempt to
decipher genetic vs. environmental factors influencing
risk, research has focused on differences between Mexico-
born women and women of Mexican descent born in the
United States. Some studies show that NTD rates are
higher in women born in Mexico than women of Mexican
descent born in the United States [6,74]. Others show rates
of U.S.-born Mexican women to be intermediate between
Mexico-born Mexican women and U.S.-born white
women, supporting environmental rather than genetic
causes [76]. Still other studies have found no association,
confounding the ability to draw definitive conclusions at
this time [77].
Research into possible genetic causes underlying the
increased risk in Hispanics is ongoing. One of the best
studied genetic polymorphisms in the folate pathway
involves 5, 10-methylenetetrahydrofolate reductase
(MTHFR) that encodes the enzyme responsible for pro-
duction of the major circulating form of folate. One par-
ticular poymorphism, the C677T allele, results in reduced
enzymatic activity and has been shown to increase the
rates of NTDs [78]. This allele has the highest frequency
in Hispanics, followed by non-Hispanic whites, and
finally by non-Hispanic blacks who have the lowest fre-
quency. These data correlate well with the racial/ethnic
trends in NTD rates. Yet, analysis of the frequency of this
allele and NTD rates worldwide presents a more confusing
picture. Although the C677T allele is common in Mexico
(and northern China) where rates are high, it also is com-
mon in southern Italy where NTD rates are low [79,80].
According to Botto, one possible explanation for this is
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nthat the ultimate fetal phenotype depends on the maternal
nutritional status and/or polymorphisms in other genes in
the folic acid and related metabolic pathways [78].
Other genes besides MTHFR have been associated with
high NTD rates in different populations, and interest in
studying an array of polymorphisms of genes in the folate
pathway and other related metabolic pathways is growing.
This is challenging research for several reasons. Gene-
gene [81] and gene-environment/nutrient [82] interactions
are likely both important determinants of risk, and genes
involved in NTDs may work at the level of the maternal
and fetal genotypic levels as well as interact together and
with environmental factors [83,84]. Much of the work to
date is characterized by small, underpowered studies that
are difficult to replicate. NTDs are complex, non-Mende-
lian traits that arise sporadically and often have only one
or two affected members even in large families. No single
gene has yet emerged as the most important genetic risk
factor. Increased efforts at gathering larger cohorts, use of
animal models, or meta-analysis may help address some
of these issues [9].
No matter what the relative contributions of genetic and
environmental factors, cultural/dietary practices among
Hispanics are also likely important. Given the heavy con-
sumption of legumes throughout Mexico and Central and
South America, the Hispanic diet is quite rich in natural
food folate [76]. However, supplement use (described
above) is low. Moreover, Hispanic women also are less
likely to benefit from folic acid added to prepared foods
and less likely than non-Hispanic white women to eat
breakfast cereals, an important source of folic acid with
some providing 0.4mg in one serving [85]. Of even greater
importance is that the Hispanic diet is based primarily on
corn flour rather than the wheat flour of the Western diet.
This is relevant because corn flour was omitted from the
mandatory fortification policy in the United States.
Hamner et al developed a model to assess the projected
effect of fortification of corn masa flour, a main ingredient
in many commonly consumed food items in Hispanic cui-
sine, such as tamales and tortillas. This model predicted a
19.9–33.1% increase in folic acid levels among Hispanic
women of childbearing years with the addition folic acid
to corn masa. The model also predicted that although for-
tification of corn masa flour would effectively target His-
panics more than other ethnic groups, predicted serum
folic acid increases among non-Hispanic white and non-
Hispanic blacks would only be 4.0% and 3.6%, respec-
tively. Accordingly, even with corn masa flour fortifica-
tion, daily intake for most Hispanics would remain well
below the 0.4mg recommendation; it is uncertain if this
intervention would translate into improved reproductive
outcomes [86]. However, it does show how important it is
to acknowledge dietary needs of different racial/ethnic
groups when countries develop their fortification policies.
It has been proposed that Hispanics may not be as sensitive
to folic acid as are other ethnic groups, or may need higher
amounts for protection [8]. However, these studies are few
in number and the rates of supplement use so low that it
is impossible to draw any meaningful conclusions. Man-
datory fortification programs and studies providing sup-
plements also tell a different story. Indeed, NTD rates
dropped by 40% after fortification was mandated in Chile
[28]. Spina bifida rates at birth in the National Hospital
dropped 74% after mandatory fortification in Costa Rica
[87], and an intervention study providing a free 5mg/week
supplement to women in a resource poor area of Mexico
was associate with a decline in NTD-affected pregnancies
of 43% [88]. Although most of the evidence showing effi-
cacy of folic acid is derived from study populations of
largely non-Hispanic whites, no conclusive evidence sug-
gests that folic acid is not equally effective in Hispanics.
It is presently unclear, however, how much of the reported
racial/ethnic differences may be attrributable to differen-
ces in prenatal diagnosis and termination rates and the type
of surveillance system used. Termination and prenatal
diagnosis rates vary by race/ethnicity [89]. If certain
racial/ethnic groups have lower rates of prenatal diagnosis
or if certain groups are less likely to terminate affected
pregnancies (because of cultural or religious reasons),
then these practices pose a serious confounding effect for
surveillance data. As one example, Williams et al [73]
used 21 birth defects surveillance systems data to analyze
NTD rates by race ethnicity. Only nine of these systems
included prenatal case ascertainment. When these nine
were analyzed separately, the prevalence of NTDs among
Hispanics was 10% higher compared to non-Hispanic
whites, but this observation was of borderline statistical
significance (PR 1.10 95% CI 1.00–1.21). This difference
rose to 42% when using data from surveillance systems
lacking prenatal case ascertainment (PR 1.42 95% CI
1.33–1.52).
7. Does the modern diet provide sufficient
folate?
A fundamental issue in answering this question is the dif-
ference between natural food folates and synthetic folic
acid. Natural food folates are ∼50% less bioavailable
compared to synthetic folic acid used in supplements and
fortification. This diminished bioavailability results from
several factors: 1) the nature of food matrix, with some
folates remaining bound and hence unavailable within the
plant material; 2) factors affecting deconjugation of the
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npolyglutamate form of folates into the monoglutamyl form
(the latter form is required for absorption in the small
intestine); and 3) losses incurred during harvesting, pro-
cessing, and preparation of foods [90]. Synthetic folic acid
is highly stable, but leafy green vegetables and legumes
undergo a loss of 50–89% of folate after cooking [91]. To
adjust for these differences, Dietary Folate Equivalents
(DFE)—defined as natural food folate + 1.7 times the
dietary folic acid—were introduced in the United States
as a tool for measuring overall folate status from both nat-
ural and synthetic sources.
In theory, today’s American diet could provide a sufficient
intake of folate, yet the foods needed to obtain this level
would likely represent a significant departure from normal
dietary habits of most women and may be impractical for
daily consumption. The usual Western diet contains about
200 mcg natural folate. The 1992 CDC guideline recom-
mending 0.4mg/d of folic acid means that a woman would
have to consume 1000 mcg/day of natural food folates to
obtain that level, taking into account the bioavailability
difference [35]. Because of this, the 1998 Food and Nutri-
tion Board of the Institute of Medicine restated the find-
ings to recommend 400mcg of synthetic folic acid in addi-
tion to the natural folates consumed in a normal, varied
diet [92]. It also is important to note that most of the evi-
dence showing a protective effect looked at synthetic folic
acid, not at the natural food folates. How effectively nat-
ural food folates might work to reduce NTD risk is
unknown [26].
Of course, the importance of overall nutritional status dur-
ing pregnancy cannot be overstated, and uncertainty about
folate levels in foods should not deter the clinician from a
discussion about healthy diet before and during preg-
nancy. A balanced, high nutrient diet contributes greatly
to fetal growth and development, promotes positive mater-
nal health outcomes, including healthy levels of preg-
nancy weight gain, and may help prevent adult onset dis-
eases later in the infant’s life [93]. Although there is a
surfeit of literature for women to read about diet and life-
style during pregnancy, many studies show that only a
very small percentage of readers actually follow this
advice, making nutrition an ongoing area of concern [94,
95]. Patient educational literature about folic acid has
increased dramatically since the 1992 CDC recommen-
dation, and high-risk women such as Hispanics are
increasingly being targeted by culture-specific literature
[96]. Good sources of dietary folate that are often cited
include legumes, orange juice, leafy green vegetables,
broccoli, and whole grains [93]. Unfortunately patient
education materials often fail to distinguish between the
wide variations in folate content in common foods. For
example, broccoli has widely different folate values
depending on whether it is cooked, raw, or frozen.
8. Besides maternal folic acid status, what
other known risk factors exist for NTD?
Whereas folic acid status is the most widely studied deter-
minant of NTD risk, other factors contribute to increased
risk. Understanding these factors is important for two rea-
sons. The first is that most (90%) of NTDs occur in women
with no personal history of an NTD-affected pregnancy,
making it impossible to use medical history as a means of
targeting all high-risk women for intervention. The second
reason lies in the ability or inability of the clinician and
the patient to modify some of these risk factors.
Obesity and diabetes have emerged as significant risk fac-
tors for NTDs. The link between diabetes and congenital
anomalies has been observed for decades, with about 10%
of babies born to diabetic mothers displaying birth defects.
These defects are wide ranging, but NTDs are among the
most common, with a 2-fold increase in risk for spina
bifida and a 3-fold increase risk for anencephaly in infants
of diabetic mothers [97]. The degree of maternal hyper-
glycemia during the first trimester is among the most
important determinants of risk, with tight glucose control
during that time leading to a reduced incidence of anoma-
lies [97]. Even in women without diabetes or obesity,
abnormal glycemic control is associated with increased
risk [98]. Obesity is also a likely risk factor, with the risk
increasing in a dose dependant fashion. Rates of prepreg-
nancy obesity have skyrocketed in the last two decades,
with a 70% increase from 1992–2004. Among women
ages 20–39, 30% are obese. A recent meta-analysis found
that compared to women of normal weight, the OR for
NTD was 1.22 (95% CI .99–1.49), 1.70 (95% CI 1.34–
2.15), and 3.11 (95% CI 1.75–5.46) among overweight,
obese, and severely obese women, respectively [99]. Why
obesity leads to increases in NTD risk is unknown, but
may be related to altered glucose metabolism [98] or con-
sumption of a diet high in calories but low in micronu-
trients [100].
Deficient or inadequate levels of vitamin B12 have been
implicated in NTD risk. Metabolically related to folic
acid, vitamin B12 is a significant element in the NTD
equation, with B12 deficiency increasing risk of NTDs
independent of folic acid status [101–103]. In one study
that stratified risk according to B12 levels, most of the risk
was found in women with levels below 250mcg/L, and
women with levels <200mcg/L were 3 times more likely
to have a NTD-affected pregnancy than were those who
had levels >400 mcg/L. It is unknown how many cases of
NTD might be prevented by increasing B12 levels in a
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npopulation exposed to folate fortification, although one
study conducted in post-fortification Canada estimated
that 34% of remaining NTDs could be attributable to low
B12 levels [103]. Debate is ongoing about adding B12 to
food through fortification, similar to folic acid, and/or
adding it to supplements [104]. Many questions about
B12, including an unexplored safety profile, the dose nee-
ded for protection, clinical outcomes data from RCTs, and
technical issues related to fortification remain unanswered
[102,105].
A wide variety of maternal exposures during pregnancy
also is associated with NTD risk. For example, maternal
hyperthermia in early pregnancy (OR 1.92, 95% CI 1.61–
2.29) increases risk, reflecting the possible teratogenic
nature of heat during embryogenesis [106]. Maternal diar-
rheal illness around the periconceptual period is an inde-
pendent risk factor as well, likely though decreased
absorption of micronutrients during the illness (OR 3.7,
95% CI 1.8–7.6) [107]. Attempting to explain the large
geographic variations in NTD risk, researchers have stud-
ied other exposures such as secondhand smoke, pesticides,
proximity to hazardous waste sites, and urban vs. rural
residence with conflicting results [108–110]. The host of
potential risk factors cited by the literature underlines the
uncertain, complex etiology of NTDs.
9. What are the rates for supplement use
among pregnant women periconceptually and
among women who could become pregnant, and
what are the barriers to supplement use and
strategies to increase use?
Many academic medical agencies endorse supplementa-
tion with folic acid at 0.4mg/d for all women ages 18–44
who are capable of becoming pregnant. Supplementation
is a United States Preventive Service Task Force
(USPSTF) Grade A recommendation (2009) and is
endorsed by the American College of Obstetricians and
Gynecologists (ACOG), the American Academy of Pedia-
trics (AAP), the American Academy of Family Practi-
tioners (AFP), and the American Academy of Neurology
(AAN) [111–112].
Despite the strong USPHF recommendation in 1992 and
public awareness campaigns carried out by the March of
Dimes, the CDC, and the Spina Bifida Association, rates
of supplement use by women remain persistently low. A
2006 report by the March of Dimes, for example, tracked
awareness and use of folic acid supplements from 1995–
2005 and found that, by 2005, 80% of women had heard
of folic acid but only 19% of women had specific knowl-
edge that folic acid prevents birth defects and even less
(7%) knew that it should optimally be taken before con-
ceiving. The percentage of women taking a daily supple-
ment increased modestly during this same decade, with
28% in 1995 and 33% in 2005 reporting use, with the latter
number representing a disheartening decrease from the
40% high in 2004 [38]. Globally, rates of folic acid use
also are low. A systematic review in 2004 reported rates
throughout the world of 0.9–50%. Predictors of low use
included young age, single status, history of unplanned
pregnancy, immigrant status, non-White race, low educa-
tional attainment, and lower income level [113–115].
Although mass media campaigns improved rates, usage
never rose above 50% [113]. These findings demonstrate
a need for further education and addressing the barriers
that exist in translating this knowledge into practice.
Several barriers to regular supplement use exist. Many
women believe there is no need to take a supplement if
they are not planning pregnancy or that folate present in
diet alone is sufficient [38]. Additionally, although 86%
of women surveyed in 2005 said that they would be willing
to take a supplement if advised by their doctor, only 26%
of women said that they had heard about folic acid from a
health-care provider [38]. A study of supplement knowl-
edge among physician and nonphysician women’s health
providers found a high level of knowledge about folic acid
in general, but only 58% of respondents knew the correct
daily recommended dose, less than a third knew the cor-
rect dose for a woman with a history of NTD pregnancy,
and only 45% of family medicine/general internal medi-
cine physicians recommended daily supplement use to
their patients [116].
Education that specifically targets women of lower edu-
cational attainment and lower SES must be made a prior-
ity, and culturally specific literature, such as that devel-
oped for Mexican American women, must be made widely
available [96]. Because more than 50% of pregnancies are
unplanned, providers must make a concerted effort to edu-
cate women during well-women visits and other pre-con-
ception contact with the health-care system [114,116].
Further research is needed on the best means to educate
women and promote behavioral changes. Such efforts
likely will involve a combination of interventions, support
from health-care providers, media attention, and creative
strategies. One approach recommends adding folic acid to
oral contraceptive pills (OCPs), in an effort to target some
of the unplanned pregnancies. This idea is being explored
by Johnson & Johnson, maker of several types of OCPs
[35].
Changing women’s behavior is a challenge in almost
every setting, but it is particularly difficult in resource-
poor areas. One potentially promising solution is the use
of once-a-week high-dose folic acid supplement. A recent
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nstudy showed that, although a once-a-week 2800mcg sup-
plement was somewhat less effective at increasing RBC
folate concentrations than was daily use, it nevertheless
increased levels to concentrations that are associated with
a reduced risk of NTDs [117]. When once-a-week 5mg
supplements were used in Nuevo Leon, Mexico, a signif-
icant reduction in NTD cases was observed over the course
of two years [88]. Further research investigating the
degree of expected benefit and the increase in compliance
over daily supplement use, if any, is needed.
10. What questions remain unanswered?
Many questions remain surrounding folic acid, fortifica-
tion policy, supplementation, and likely or projected
impact on NTDs, public health, and a host of other disea-
ses. Some of the most pressing issues involve recent ques-
tions about the role of folic acid in cancer promotion and
prevention. Recent data from the United States, Canada,
and Chile [118–121] describe a significant increase in
colon cancer cases observed shortly after the initiation of
fortification in each country. This change cannot be
accounted for by increased screening. Although these data
show only a correlation in time, the trends are disturbing
and may fit with the emerging biological role of folic acid
in cancer promotion and prevention. Emerging research
shows that folic acid may play dual and opposite roles in
relation to cancer promotion [120–122]. Because folate
deficiency long has been suspected to promote cancer
through genomic destabilization perhaps via increased
homocysteine levels, impaired methylation, uracil misin-
corporation, or double strand DNA breaks leading to chro-
mosomal damage [123,124], adequate levels of folate
could be protective against carcinogenesis by dampening
these effects. However, given the critical role of folate in
nucleic acid biosynthesis, it also may have a role in cancer
promotion in susceptible individuals. In patients harbor-
ing preneoplastic and neoplastic lesions, exposure to extra
folate (through supplementation or fortification) could
promote cellular proliferation and cancer growth [121,
125]. Additionally, studies have shown conflicting or
equivocal results for the role of folic acid in other cancers,
including breast [126,127], prostate [128], and neuroblas-
toma [129].
The role of folic acid in cardiovascular diseases also is an
area of active research. Folic acid long has been assumed
to promote cardiovascular health. Observational epide-
miologic studies show an inverse relationship between
folate intake and CVD [130]. Several RCTs have shown
that increases in folic acid led to dramatic reduction in
plasma homocysteine levels, which long have been linked
to CVD [131]. Recent studies failed to show evidence of
a protective effect, and one recent meta-analysis showed
no reduced risk of cardiovascular or all-cause mortality in
patients with preexisting CV disease [132]. A 2006 RCT
looking at the benefits of folic acid supplementation in
women at high risk of CV disease showed no reduction in
CV events, despite evidence of reduced plasma homocys-
teine in the supplementation group [133]. More studies,
especially those that focus on the role of folic acid in pri-
mary prevention of CV disease and studies that follow
cohorts over long time periods are needed to address this
issue.
Other ongoing areas of uncertainty relate to a variety of
mostly pediatric diseases and other congenital malforma-
tions distinct from NTD. A recent meta-analysis included
studies that looked at the effect of prenatal multivitamins
containing folic acid on rates of birth defects and found
decreased risk for congenital heart defects, cleft palate,
oral cleft, urinary tract anomalies, and congenital hydro-
cephalus in women who took prenatal supplements [134].
Additionally, other data suggest that, along with a
decrease in rates of congenital anomalies, the severity of
the remaining defects has decreased [135]. A reported rise
in autism which coincided with the beginning of fortifi-
cation in the United States has been hypothesized to be a
result of increased in utero exposure to folic acid [136,
137]. Additionally, a link between the rise in asthma and
allergic diseases of childhood and the increase in prenatal
folic acid use [138] has been suggested by studies in both
humans [139] and mice [140]. Although intriguing, these
issues will require further research before any definitive
statements can be made.
Additional issues
Fortification—Not all foods that are currently fortified
would facilitate increasing folic acid intakes among all
women of reproductive age to a specific level, because
numerous women of specific ethnic heritages do not eat
fortified foods on a regular basis, if ever. Additionally,
government-mandated fortification of food products with
folic acid to reduce the incidence of birth defects, although
well-established in cereal and bakery products, appears to
be conspicuously ignored by the dairy, beverage, and pre-
pared food industries. One reason for this may be because
of the decline in taste and flavor caused by folic acid at
fortification levels in such foods.
Cereals and cereal-based foods meet the necessary criteria
of being technically amenable to folic acid fortification
under existing fortification legislation. Yogurt and other
dairy products, however, deteriorate in taste and flavor
with the addition of folic acid at fortification levels. The
food industry continues to be challenged in making
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nhealthy products taste good while concurrently addressing
a new market need – new avenues for folic acid fortifica-
tion. In addition, the increasing levels of wheat and gluten
intolerance and individual preferences are creating a need
for new ingredient technologies to facilitate including
folic acid in new food groups.
The provision of foods fortified with folic acid does not
come without significant costs for the food industry. Gen-
erally speaking, cereal, juice, and dairy markets are
extremely competitive and leave little financial incentive
for developing marketing programs to educate target audi-
ences. Additionally, not all cereal foods are fortified
(e.g., corn tortillas). There also is the issue of allergy to
synthetic folic acid, the ingredient of choice in most for-
tified foods. Although rare, allergies to synthetic folic acid
are likely to become more common, given the rate of for-
tification with this vitamin. Physicians should consider
folic acid allergies in the differential diagnosis of idio-
pathic anaphylaxis in patients with suspected grain aller-
gies [141].
Because folate supplementation is particularly important
at least three months before and after conception, the U.S.
Food and Drug Administration (FDA) recently approved
a new oral contraceptive, Beyaz™ (drospirenone/ethinyl
estradiol/levomefolate calcium tablets and levomefolate
calcium tablets) to increase folate levels in women who
choose an oral contraceptive as their preferred method of
birth control. Putting folate in birth control pills addresses
the public health need for increased folate levels in young
women and reduces the risk of a neural tube defect in a
pregnancy conceived while taking it or shortly after dis-
continuing it. The popularity of Beyaz among young
women for its effect on acne and Premenstrual Dysphoric
Disorder also may help with regular folate intake for this
population.
Cancer—Some evidence indicates that folic acid may
facilitate the preliminary stages of specific malignant pro-
cesses. Hospitalization rates for colon cancer among men
and women age 45 and older in Chile more than doubled
after folic acid fortification was introduced in the country
in 2000 [142,143]. Additionally, two Norwegian studies,
the Norwegian Vitamin Trial and the Western Norway B
Vitamin Intervention Trial, found that supplementation
with 800mcg/d of folic acid, B12, and B6 for more than
three years increased the risk of lung cancer by 21%. An
analysis of these latter two studies, designed to study the
effects of higher dose folic acid and vitamin B12 on reduc-
ing cardiovascular deaths by lowering plasma homocys-
teine levels, showed that high dose (synthetic) folic acid
supplementation unexpectedly may increase cancer and
all-cause mortality [144]. It is important to note, however,
that the dose used in these two trials is twice that recom-
mended on an international basis for pregnancy-related
intakes (see above). Systematic studies of the safety of
high doses of folic acid are lacking, and it is axiomatic that
absence of data does not imply assurance of safety. No
single2 agency is tasked with the responsibility of moni-
toring the long-term or overall safety of the fortification
program. The lack of systematic safety studies means
uncertainty about which outcomes are the most sensitive
predictors of risk. The issue is proving to be of great
urgency to researchers, governments, and industry, given
the level of mandatory folic acid fortification in the United
States and other countries and the many years of education
on the health benefits associated with folic acid that has
been directed at consumers.
Conclusion
Because of ongoing and substantial efforts and collabora-
tion of scientists, public-health authorities, nonprofit
groups, and governmental agencies, women in many areas
of the world now benefit from significant improvements
in their folic acid status through the use of folic acid sup-
plementation and fortification, alone or together. There
efforts should continue, with a particular focus on inno-
vative public-health strategies that target population spe-
cific barriers to supplement use. Additionally, the rela-
tionship folic acid to the health of people of all ages and
with many different health conditions, especially cancer,
is among the field’s most pressing questions.
Despite all efforts, many women may remain at risk of
having a folic acid-preventable NTD-affected pregnancy.
Additional investigation into gene-gene and gene-envi-
ronment risk factors is an exciting avenue of research that
has only just begun. Eventually this research could lead to
tailoring of prevention measures to specific risk groups.
Work on potentially modifiable risk factors, including
vitamin B12 status, is a very promising avenue of investi-
gation as research expands beyond folic acid to explore
other determinants of these complex anomalies. Surveil-
lance systems must be in place to detect as many cases as
possible, particularly those that are prenatally diagnosed.
Women must have access to second trimester screening
and advanced diagnosis, at no cost to the patient. This is
becoming even more important given the emerging
options for affected babies, including promising fetal sur-
gery for spina bifida-affected neonates. Research on
NTDs in different racial/ethnic groups, especially in the
Hispanic population, also must continue. Minority groups
in the United States too often are disproportionally bur-
dened by poor health outcomes. Public health authorities
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nmust ensure that minority women are able to reap the
maximum benefit from NTD prevention, detection, and
treatment efforts. This multifaceted approach may lead to
a time when no woman will have to suffer through a NTD-
affected pregnancy.
Finally, although this review has focused on the effect of
folic acid intake and supplementation in women, recent
evidence suggests that it may be of great importance in
men, not only in terms of potential cancer and/or other
associated risks, but in terms of improving sperm quality
in men who are partners to women who are considered
subfertile. In particular, men who take supplements con-
taining folic acid have improved sperm counts, motility,
and decreased numbers of abnormal forms [145].
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